Mutual of America Capital Management LLC lowered its stake in Axon Enterprise, Inc. (NASDAQ:AXON – Free Report) by 2.2% in the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 13,133 shares of the biotechnology company’s stock after selling 289 shares during the quarter. Mutual of America Capital Management LLC’s holdings in Axon Enterprise were worth $3,864,000 as of its most recent filing with the SEC.
A number of other large investors have also modified their holdings of AXON. Motley Fool Asset Management LLC boosted its holdings in Axon Enterprise by 238.7% in the first quarter. Motley Fool Asset Management LLC now owns 492,140 shares of the biotechnology company’s stock valued at $153,981,000 after purchasing an additional 346,838 shares during the last quarter. 1832 Asset Management L.P. purchased a new position in Axon Enterprise in the first quarter valued at about $81,630,000. Vanguard Group Inc. boosted its holdings in Axon Enterprise by 2.7% in the first quarter. Vanguard Group Inc. now owns 8,143,306 shares of the biotechnology company’s stock valued at $2,547,878,000 after purchasing an additional 212,401 shares during the last quarter. Goldman Sachs Group Inc. boosted its holdings in Axon Enterprise by 110.0% in the fourth quarter. Goldman Sachs Group Inc. now owns 276,011 shares of the biotechnology company’s stock valued at $71,302,000 after purchasing an additional 144,568 shares during the last quarter. Finally, Swedbank AB purchased a new position in Axon Enterprise in the first quarter valued at about $39,923,000. Institutional investors and hedge funds own 79.08% of the company’s stock.
Insider Activity at Axon Enterprise
In related news, Director Michael Garnreiter sold 1,000 shares of the firm’s stock in a transaction that occurred on Monday, September 16th. The stock was sold at an average price of $380.99, for a total value of $380,990.00. Following the sale, the director now directly owns 27,259 shares in the company, valued at approximately $10,385,406.41. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In related news, Director Julie A. Cullivan sold 900 shares of the firm’s stock in a transaction that occurred on Thursday, September 5th. The stock was sold at an average price of $353.53, for a total value of $318,177.00. Following the sale, the director now directly owns 3,653 shares in the company, valued at approximately $1,291,445.09. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Michael Garnreiter sold 1,000 shares of the firm’s stock in a transaction that occurred on Monday, September 16th. The shares were sold at an average price of $380.99, for a total value of $380,990.00. Following the completion of the sale, the director now owns 27,259 shares in the company, valued at $10,385,406.41. The disclosure for this sale can be found here. Insiders have sold a total of 317,981 shares of company stock worth $115,662,734 in the last three months. 6.10% of the stock is owned by company insiders.
Wall Street Analysts Forecast Growth
Read Our Latest Report on AXON
Axon Enterprise Stock Up 0.9 %
Shares of Axon Enterprise stock opened at $393.29 on Monday. The company has a current ratio of 2.88, a quick ratio of 2.52 and a debt-to-equity ratio of 0.35. The business’s 50 day simple moving average is $348.04 and its 200-day simple moving average is $317.24. The stock has a market capitalization of $29.68 billion, a price-to-earnings ratio of 115.00, a PEG ratio of 10.34 and a beta of 0.94. Axon Enterprise, Inc. has a twelve month low of $189.12 and a twelve month high of $393.58.
Axon Enterprise (NASDAQ:AXON – Get Free Report) last announced its quarterly earnings results on Tuesday, August 6th. The biotechnology company reported $1.20 earnings per share for the quarter, topping analysts’ consensus estimates of $1.02 by $0.18. Axon Enterprise had a return on equity of 9.34% and a net margin of 16.06%. The business had revenue of $504.00 million for the quarter, compared to analysts’ expectations of $478.35 million. During the same period in the prior year, the firm earned $0.80 EPS. The business’s quarterly revenue was up 34.5% on a year-over-year basis. Equities research analysts forecast that Axon Enterprise, Inc. will post 1.79 earnings per share for the current year.
Axon Enterprise Profile
Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.
Read More
- Five stocks we like better than Axon Enterprise
- 3 Grocery Stocks That Can Help Take a Bite Out of Inflation
- 3 Stocks That Could Rise on European Bank Interest Rate Cuts
- The 3 Best Blue-Chip Stocks to Buy Now
- Take Advantage of Village Farms Stock as Cannabis Market Evolves
- Investing in Travel Stocks Benefits
- MarketBeat Week in Review – 9/16 – 9/20
Want to see what other hedge funds are holding AXON? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Axon Enterprise, Inc. (NASDAQ:AXON – Free Report).
Receive News & Ratings for Axon Enterprise Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axon Enterprise and related companies with MarketBeat.com's FREE daily email newsletter.